Table 6

Multivariate Cox model (DFS) including interaction of uPA/PAI-1 with adjuvant treatment in breast cancer patients with four or more involved axillary nodes (n = 784)a

Analysis was stratified by the Center: seven patients were censored before the first event in the stratum, 501 events total. Stages of analysis are as in Table 3 <$REFLINK> .

Significant factorsbCoding for interpretation of βFinal model
PβHR (95% CI)
Involved lymph nodes10 nodes vs. 4 nodes<0.0015.362.1 (1.6–2.8)d
AgeFractional rank0.002−0.620.54 (0.36–0.80)
Tumor stageRest (1) vs. pT1/pT2 (0)0.0010.351.41 (1.16–1.73)
PgRFractional rank0.001−0.540.59 (0.43–0.80)
uPA/PAI-1High (1) vs. low (0)0.0133.0220.5 (1.9–220)
Adjuvant chemotherapyYes (1) vs. no (0)0.034−0.340.71 (0.52–0.97)
Adjuvant endocrine therapyYes (1) vs. no (0)0.002−0.390.68 (0.53–0.87)
Interaction, chemotherapy uPA/PAI-1Both 1 vs. either or both 00.040−0.420.66 (0.44–0.98)
Interaction, involved lymph nodes × uPA/PAI-1If low uPA/PAI-1: zero0.039−2.790.061 (0.004–0.87)
If high uPA/PAI-1: fractional rank of nodes
  • a Two of 786 were excluded because of missing information on adjuvant chemotherapy.

  • b Coding of variables as reported in “Materials and Methods.”

  • c Hazard for fractional rank = 1 compared with fractional rank = 0.

  • d HR for patients with 10 positive nodes compared with patients with four positive nodes, CI is approximate because of fractional ranks.